The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Kidney International

Volumn 65, Issue 3, 2004, Pages 1041-1049

  Høieggen, Aud ^a   Alderman, Michael H ^b   Kjeldsen, Sverre E ^b   Julius, Stevo ^b   Devereux, Richard B ^b   De Faire, Ulf ^b   Fyhrquist, Frej ^b   Ibsen, Hans ^b   Kristianson, Krister ^b   Lederballe Pedersen, Ole ^b   Lindholm, Lars H ^b   Nieminen, Markku S ^b   Omvik, Per ^b   Oparil, Suzanne ^b   Wedel, Hans ^b   Chen, Cong ^b   Dahlöf, Björn ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Atenolol; Cardiovascular risk factors; Hypertension; LIFE study; Losartan; Serum uric acid

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN; URIC ACID;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COVARIANCE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; STANDARD; STROKE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 10744221128     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00484.x     Document Type: Article

References (60)

1. KLEIN R, KLEIN BE, CORNONI JC, et al: Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 132:401-410, 1973
2. BENGTSSON C, LAPIDUS L, STENDAHL C, WALDENSTROM J: Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 224:549-555, 1988
3. LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 27:63-68, 1996
4. ALDERMAN MH, COHEN H, MADHAVAN S, KIVLIGHN S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144-150, 1999
5. GERTLER MM, GARN SM, LEVINE SA: Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34:1421-1431, 1951
6. FREEDMAN DS, WILLIAMSON DF, GUNTER EW, BYERS T: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637-644, 1995
7. PERSKY VW, DYER AR, IDRIS-SOVEN E, et al: Uric acid: A risk factor for coronary heart disease? Circulation 59:969-977, 1979
8. CULLETON BF, LARSON MG, KANNEL WB, LEVY D: Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 131:7-13, 1999
9. LEVINE W, DYER AR, SHEKELLE RB, et al: Serum uric acid and 11.5-year mortality of middle-aged women: Findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 42:257-267, 1989
10. FANG J, ALDERMAN MH: Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283:2404-2410, 2000
11. DYER AR, LIU K, WALSH M, et al: Ten-year incidence of elevated blood pressure and its predictors: The CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 13:13-21, 1999
12. WANNAMETHEE SG, SHAPER AG, DURRINGTON PN, et al: Hypertension, serum insulin, obesity and the metabolic syndrome. J Hum Hypertens 12:735-741, 1998
13. FROST PH, DAVIS BR, BURLANDO AJ, et al: Coronary heart disease risk factors in men and women aged 60 years and older: Findings from the Systolic Hypertension in the Elderly Program. Circulation 94:26-34, 1996
14. VERDECCHIA P, SCHILLACI G, REBOLDI G, et al: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study. Hypertension 36:1072-1078, 2000
15. ANKER SD, LEYVA F, POOLE-WILSON PA, COATS AJS: Uric acid independent predictor of impaired prognosis in patients with chronic heart failure. J Am Coll Cardiol 31:154A, 1998
16. BUTLER R, MORRIS AD, BELCH JJ, et al: Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746-751, 2000
17. DOEHNER W, SCHOENE N, RAUCHHAUS M, et al: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 105:2619-2624, 2002
18. LEYVA F, ANKER S, SWAN JW, et al: Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18:858-865, 1997
19. MUSTARD JF, MURPHY EA, OGRZYLO MA, et al: Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J 89:1207-1211, 1963
20. HØIEGGEN A, FOSSUM E, REIMS H, KJELDSEN SE: Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy. Blood Pressure 12:104-110, 2003
21. NEWLAND H: Hyperuricemia in coronary, cerebral and peripheral arterial disease: An explanation. Med Hypotheses 1:152-155, 1975
22. MESSERLI FH, FROHLICH ED, DRESLINSKI GR, et al: Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Arch Intern Med 93:817-821, 1980
23. MATTEI P, ARZILLI F, GIOVANNETTI R, et al: Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest 27:755-760, 1997
24. JOHNSON RJ, KANG D-H, FEIG D, et al: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183-1190, 2003
25. BURNIER M, RUTSCHMANN B, NUSSBERGER J, et al: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339-347, 1993
26. BURNIER M, ROCH-RAMEL F, BRUNNER HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 49:1787-1790, 1996
27. SOFFER BA, WRIGHT JT JR, PRATT JH, et al: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26:112-117, 1995
28. DAHLÖF B, DEVEREUX RB, DE FAIRE U, FOR THE LIFE STUDY GROUP: The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: Rationale, design, and methods. Am J Hypertens 10:705-713, 1997
29. DAHLÖF B, DEVEREUX RB, JULIUS S, et al: Characteristics of 9,194 patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 32:989-997, 1998
30. KJELDSEN SE, DAHLÖF B, DEVEREUX RB, et al: Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint. Am J Hypertens 13:899-906, 2000
31. DAHLÖF B, DEVEREUX RB, KJELDSEN SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995-1003, 2002
32. IRGENS-MOLLER L, HEMMINGSEN L, HOLM J. Diagnostic value of microalbuminuria in pre-eclampsia. Clin Chim Acta 157:295-298, 1986
33. BORCH-JOHNSEN K, WENZEL H, VIBERTI GC, MOGENSEN CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 306:1722-1725, 1993
34. JENSEN JS, CLAUSEN P, BORCH-JOHNSEN K, et al: Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 12(Suppl 2):6-9, 1997
35. WHO STUDY GROUP: Diabetes mellitus, Geneva, Switzerland, World Health Organization. Technical Report Series 727:1-113, 1985
36. CHEN C, WANG HW, SNAPINN SM: Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med 22:3449-3459, 2003
37. ANDERSON KM, WILSON PW, ODELL PM, KANNEL WB: An updated coronary risk profile. A statement for health professionals. Circulation 83:356-362, 1991
38. BLOOD PRESSURE LOWERING TREATMENT TRIALISTS' COLLABORATION: Effects of ACE inhibitors, calcium-antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 355:1955-1964, 2000
39. BROWN MJ, PALMER CR, CASTAIGNE A, et al: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366-372, 2000
40. RUILOPE LM, SALVETTI A, JAMERSON K, et al: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12:218-225, 2001
41. TYKARSKI A: Evaluation of renal handling of uric acid in essential hypertension: Hyperuricemia related to decreased urate secretion. Nephron 59:364-368, 1991
42. STRAZZULO P, BARBA G, CAPPUCCIO FP, et al: Altered renal sodium handling in men with abdominal adiposity: A link to hypertension. J Hypertens 19:2157-2164, 2001
43. JOHNSON RJ, HERRERA-ACOSTA J, SCHREINER GF, RODRIGUEZ-ITURBE B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923, 2002
44. SAITO I, SARUTA T, KONDO K, et al: Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 26:241-247, 1978
45. KANG DH, NAKAGAWA T, FENG L, et al: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888-2897, 2002
46. MAZZALI M, HUGHES J, KIM YG, et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101-1106, 2001
47. MAZZALI M, KANELLIS J, HAN J, et al: Hyperuricemia induces a primary renal artereriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997, 2002
48. WATANABE S, KANG DH, FENG L, et al: Uric acid, hominoid evolution, and the pathogenesis of salt sensitivity. Hypertension 40:355-360, 2002
49. ACHESON RM, O'BRIEN WM: Dependence of serum-uric-acid on haemoglobin and other factors in the general population. Lancet 2:777-778, 1966
50. LOWE GD, LEE AJ, RUMLEY A, et al: Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 96:168-173, 1997
51. LEE AJ, MOWBRAY PI, LOWE GD, et al: Blood viscosity and elevated carotid intima-media thickness in men and women: The Edinburgh Artery Study. Circulation 97:1467-1473, 1998
52. ERIKSSEN G, THAULOW E, SANDVIK L, et al: Haematocrit: A predictor of cardiovascular mortality? J Intern Med 234:493-499, 1993
53. KJELDSEN SE, DAHLÖF B, DEVEREUX RB, et al: Predictors of cardiovascular events in hypertensive patients with left ventricular hypertrophy. J Hypertens 18(Suppl 2):S91, 2000
54. LAL SM, TRIVEDI HS, Ross G JR: Long-term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients. Int J Artif Organs 18:13-16, 1995
55. KLAASSEN RJ, VAN GELDER T, RISCHEN-VOS J, et al: Losartan, an angiotensin-II receptor antagonist, reduces haematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 64:780-782, 1997
56. WANG AY, YU AW, LAM CW, et al: Effects of losartan or enalapril on haemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 39:600-608, 2002
57. NICHOLLS A, SNAITH ML, SCOTT JT: Effect of oestrogen therapy on plasma and urinary levels of uric acid. BMJ 1:449-451, 1973
58. SUMINO H, ICHIKAWA S, KANDA T, et al: Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 354:650, 1999
59. WINGROVE CS, WALTON C, STEVENSON JC: The effect of menopause on serum uric acid levels in non-obese healthy women. Metabolism 47:435-438, 1998
60. FRANSE LV, PAHOR M, DI BARI M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18:1149-1154, 2000